Targeting of B cells in SLE: Rationale and therapeutic opportunities

Bulletin of the NYU Hospital for Joint Diseases

Volumn 64, Issue 1-2, 2006, Pages 51-56

  Silverman, Gregg J ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TOLL LIKE RECEPTOR;

ANTIBODY PRODUCING CELL; ANTIBODY PRODUCTION; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; CONFERENCE PAPER; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; INNATE IMMUNITY; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION;

ANIMALS; AUTOANTIBODIES; B-LYMPHOCYTES; CELL SURVIVAL; HUMANS; IMMUNOLOGIC FACTORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PROGNOSIS;

EID: 33750315937     PISSN: 19369719     EISSN: 19369727     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (46)

1. Diamond B, Katz JB, Paul E, Aranow C, Lustgarten D, Scharff MD. The role of somatic mutation in the pathogenic anti-DNA response. Annu Rev Immunol. 1992;10:731-57.
2. Smeenk RJ, van den Brink HG, Brinkman K, Termaat RM, Berden JH, Swaak AJ. Anti-dsDNA: choice of assay in relation to clinical value. Rheumatol Int. 1991;11:101-7.
3. Yurasov S, Wardemann H, Hammersen J, et al. Defective B cell tolerance checkpoints in systemic lupus erythematosus. J Exp Med. 2005;201:703-11.
4. D'Andrea DM, Coupaye-Gerard B, Kleyman TR, Foster MH, Madaio MP. Lupus autoantibodies interact directly with distinct glomerular and vascular cell surface antigens. Kidney Int. 1996;49:1214-21.
5. Liang Z, Xie C, Chen C, et al. Pathogenic profiles and molecular signatures of antinuclear autoantibodies rescued from NZM2410 lupus mice. J Exp Med. 2004;199:381-98.
6. Bernstein K, Bolshoun D, Gilkeson G, Munns T, Lefkowith JB. Detection of glomerular-binding immune elements in murine lupus using a tissue-based ELISA. Clin Exp Immunol. 1993;91:449-55.
7. Sekine H, Watanabe H, Gilkeson GS. Enrichment of antiglomerular antigen antibody-producing cells in the kidneys of MRL/MpJ-Fas(lpr) mice. J Immunol. 2004;172:3913-21.
8. Silverman GJ, Looney RJ, Warmoth K, Germar K, Sanz I, Anolik J: Use of multiplex autoantigen arrays to characterize autoantibody profiles in SLE patients treated with rituximab. Poster presented at: American College of Rheumatology Annual Scientific Meeting; November, 2005; San Diego, Calif.
9. Ravetch JV, Bolland S. IgG Fc receptors. Annu Rev Immunol. 2001;19:275-90.
10. Shushakova N, Skokowa J, Schulman J, et al. C5a anaphylatoxin is a major regulator of activating versus inhibitory FcgammaRs in immune complex-induced lung disease. J Clin Invest. 2002;110:1823-30.
11. Aringer M, Graninger WB, Steiner G, Smolen JS. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum. 2004;50:3161-9.
12. Harris DP, Goodrich S, Mohrs K, Mohrs M, Lund FE. Cutting edge: the development of IL-4-producing B cells (B effector 2 cells) is controlled by TL-4, IL-4 receptor alpha, and Th2 cells. J Immunol. 2005;175:7103-7.
13. Harris DP, Goodrich S, Gerth AJ, Peng SL, Lund FE. Regulation of IFN-gamma production by B effector 1 cells: essential roles for T-bet and the IFN-gamma receptor. J Immunol. 2005;174:6781-90.
14. Roosnek E, Lanzavecchia A. Efficient and selective presentation of antigen-antibody complexes by rheumatoid factor B cells. J Exp Med. 1991;173:487-9.
15. Chesnut RW, Grey HM. Antigen presentation by B cells and its significance in T-B interactions. Adv Immunol. 1986;39:51-94.
16. Chen PP, Fong S, Carson DA. Rheumatoid factor. Rheum Dis Clin North Am. 1987;13:545-68.
17. Hooks JJ, Jordan GW, Cupps T, Moutsopoulos HM, Fauci AS, Notkins AL. Multiple interferons in the circulation of patients with systemic lupus erythematosus and vasculitis. Arthritis Rheum. 1982;25:396-400.
18. Ytterberg SR, Schnitzer TJ. Serum interferon levels in patients with systemic lupus erythematosus. Arthritis Rheum. 1982;25:401-6.
19. Lovgren T, Eloranta ML, Bave U, Alm GV, Ronnblom L. Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum. 2004;50:1861-72.
20. Kawai T, Akira S. Pathogen recognition with Toll-like receptors. Curr Opin Immunol. 2005;17:338-44.
21. Rifkin IR, Leadbetter EA, Busconi L, Viglianti G, Marshak-Rothstein A. Toll-like receptors, endogenous ligands, and systemic autoimmune disease. Immunol Rev. 2005;204:27-42.
22. Boule MW, Broughton C, Mackay F, Akira S, Marshak-Rothstein A, Rifkin IR. Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatin-immunoglobulin G complexes. J Exp Med. 2004;199:1631-40.
23. Jego G, Palucka AK, Blanck JP, Chalouni C, Pascual V, Banchereau J. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity. 2003;19:225-34.
24. Litinskiy MB, Nardelli B, Hilbert DM, et al. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol. 2002;3:822-9.
25. Mackay F, Tangye SG. The role of the BAFF/APRIL system in B cell homeostasis and lymphoid cancers. Curr Opin Pharmacol. 2004;4:347-54.
26. Cassese G, Lindenau S, de Boer B, et al. Inflamed kidneys of NZB / W mice are a major site for the homeostasis of plasma cells. Eur J Immunol. 2001;31:2726-32.
27. Alexopoulos E, Seron D, Hartley RB, Cameron JS. Lupus nephritis: correlation of interstitial cells with glomerular function. Kidney Int. 1990;37:100-9.
28. Jeruc J, Jurcic V, Vizjak A, et al. Tubulo-interstitial involvement in lupus nephritis with emphasis on pathogenesis. Wien Klin Wochenschr. 2000;112:702-6.
29. D'Agati VD, Appel GB, Estes D, Knowles DM 2nd, Pirani CL. Monoclonal antibody identification of infiltrating mononuclear leukocytes in lupus nephritis. Kidney Int. 1986;30:573-81.
30. Furie R. Abetimus sodium (riquent) for the prevention of nephritic flares in patients with systemic lupus erythematosus. Rheum Dis Clin North Am. 2006;32:149-56.
31. Goodyear CS, Silverman GJ. Death by a B cell superantigen: in vivo VH-targeted apoptotic supraclonal B cell deletion by a staphylococcal toxin. J Exp Med. 2003;197:1125-39.
32. Goodyear CS, Silverman GJ. Staphylococcal toxin induced preferential and prolonged deletion of innate-like B lymphocytes. Proc Natl Acad Sci. 2004;101:11392-7.
33. Silverman GJ, Goodyear CS. Confounding B-cell defenses: lessons from a staphylococcal superantigen. Nat Rev Immunol. 2006;6:465-75.
34. Gendreau RM. A randomized double-blind sham-controlled trial of the Prosorba column for treatment of refractory rheumatoid arthritis. Ther Apher. 2001;5;79-83.
35. Goodyear CS, Sugiyama F, Silverman GJ: Temporal and dose-dependent relationships between in vivo BCR-targeted proliferation and deletion induced by a microbial B-cell toxin. J Immunol. 2006;176:2262-71.
36. Silverman, GJ, Goodyear CS, Siegel DL. On the mechanism of protein A immunomodulation. Transfusion. 2005;45 274-80.
37. Viau M, Zouali M. Effect of the B cell superantigen protein A from S. aureus on the early lupus disease of (NZBxNZW) F1 mice. Mol Immunol. 2005;42:849-55.
38. Wallace DJ, Lisse J, Stohl W, et al. Belimumab, A fully human monoclonal antibody to B-lymphocyte stimulator (BLyS), shows bioactivity and reduces systemic lupus erythematosus disease activity. Poster presented at: European League Against Rheumatism Annual Scientific Meeting; June, 2006; Amsterdam, Netherlands.
39. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83:435-45.
40. Cohen SB, Greenwald M, Dougados MR, et al. Efficacy and safety of rituximab in active RA patients who experienced an inadequate response to one or more anti-TNF therapies (REFLEX study). Poster presented at: American College of Rheumatology Annual Scientific Meeting; November, 2005; San Diego, Calif.
41. Silverman GJ. Therapeutic B cell depletion and regeneration in rheumatoid arthritis: emerging patterns and paradigms. Arthritis Rheum. 2006;54:2356-67.
42. Looney RJ, Anolik JH, Campbell D, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 2004;50:2580-9.
43. Leandro M J, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. 2002;146:2673-7.
44. Albert A, Stansberry J, Kolasinski S, Tsai D, Kamoun M, Eisenberg R. A phase I trial of rituximab (anti-CD20) for treatment of systemic lupus erythematosus. Poster presented at: American College of Rheumatology Annual Scientific Meeting; October 16-21, 2004; San Antonio, Tex.
45. Sfikakis PP, Boletis JN, Lionaki S, et al. Remission of proliferative nephritis following anti-B cell therapy is preceded by downregulation of the T cell costimulatory molecule CD40-Ligand. Arthritis Rheum. 2005;52:501-13.
46. Silverman GJ. Anti-CD20 therapy in SLE: A Step Closer to the Clinic. Arthritis Rheum. 2005;52:371-7.